Praluent Cost in Kentucky 2026: Prices, Medicaid, Insurance, and Compounding Options

What Does Praluent Actually Cost in Kentucky in 2026?

The manufacturer's list price for Praluent sits at roughly $580 per month in 2026, a figure that has changed very little since Regeneron and Sanofi introduced a lower-list-price version in 2019 [1]. Without insurance or a savings program, a Kentucky patient filling a 30-day supply at a retail pharmacy will pay close to that amount out of pocket. That is the cash-pay ceiling, not the floor. Actual patient cost depends on insurance tier, step-therapy requirements, copay assistance eligibility, and whether a patient qualifies for compounded alirocumab through a 503A pharmacy.

Alirocumab is a fully human monoclonal antibody targeting PCSK9. By blocking PCSK9, it prevents LDL-receptor degradation, leaving more receptors available to clear LDL-C from circulation [2]. The FDA approved Praluent in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy [3].

In ODYSSEY OUTCOMES (N=18,924), patients randomized to alirocumab 75 mg to 150 mg every two weeks achieved a 54.7% reduction in LDL-C from baseline compared with placebo at 48 months, and the trial reported a 15% relative risk reduction in the composite primary endpoint of major adverse cardiovascular events (MACE) versus placebo (P<0.001) [4]. The absolute risk reduction was 1.7 percentage points over a median follow-up of 2.8 years, giving a number needed to treat of approximately 59 [4].

The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction states: "In patients with very high-risk ASCVD who require additional LDL-C lowering despite maximally tolerated statin and ezetimibe therapy, a PCSK9 inhibitor is recommended (Class I, Level A)" [5]. That guideline framework is precisely the clinical setting in which Kentucky patients most often seek alirocumab.

Kentucky Medicaid Coverage for Praluent: The Current Status

Kentucky Medicaid does not cover Praluent under standard formulary criteria for most patients as of 2026. The program has historically excluded branded PCSK9 inhibitors because of their high list price and because generic statins plus ezetimibe are available at low cost on the preferred drug list [6]. Some plans within the Medicaid managed-care organizations operating in Kentucky (Aetna Better Health, Humana CareSource, Molina, UnitedHealthcare Community Plan, WellCare) may offer limited exceptions through a prior authorization pathway, but approval rates for those exceptions remain low.

Patients with homozygous familial hypercholesterolemia (HoFH) face an even narrower pathway. Alirocumab's FDA label for HoFH was updated in 2023 to include adjunctive use in adults and pediatric patients 18 years and older, but Medicaid formulary inclusion has not followed automatically [3].

The Kentucky Department for Medicaid Services publishes preferred drug lists quarterly. Patients and prescribers should check the most current list at the Kentucky Medicaid portal before assuming coverage. A formal prior authorization request, supported by lipid panel results, a documented trial of high-intensity statin therapy, and LDL-C values above guideline thresholds, may shift the outcome.

"Step therapy requirements for PCSK9 inhibitors continue to be one of the most common barriers to access for patients with familial hypercholesterolemia," according to the American Heart Association's 2023 scientific statement on FH [7].

Commercial Insurance and Prior Authorization in Kentucky

Most commercial insurers operating in Kentucky place Praluent on Tier 4 or Tier 5 of their formularies, which can mean a patient copay of $200 to $400 per month even after insurance processes the claim [8]. Prior authorization is nearly universal. Typical PA requirements include:

• Documentation of a high-intensity statin trial (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 days
• A baseline LDL-C at or above 70 mg/dL for ASCVD patients or at or above 100 mg/dL for HeFH patients
• A diagnosis of HeFH confirmed by genetic testing or clinical criteria (Dutch Lipid Clinic Network score 6 or higher), or documented ASCVD
• Evidence that ezetimibe was trialed or is contraindicated [5]

Step therapy requirements vary by plan. Some Kentucky Anthem Blue Cross Blue Shield plans, for example, require a documented trial of evolocumab (Repatha) before approving alirocumab, or vice versa. Aetna's 2025 clinical policy bulletin specifies a minimum 12-week statin optimization period before PCSK9 inhibitor authorization [9].

Appeals are worth filing. A retrospective analysis published in JAMA Internal Medicine found that physician-led PA appeals for cardiovascular medications succeeded at a rate of 53% when supported by guideline-concordant documentation [10]. A cardiologist or lipidologist co-signing the appeal letter materially improves the odds.

The Regeneron/Sanofi Praluent Savings Card: How It Works in Kentucky

Commercially insured Kentucky patients who do not use Medicaid, Medicare Part D, or any other federal health program may use the Regeneron/Sanofi Praluent CoPay Card. Under this program, eligible patients pay $0 per month for Praluent, with the manufacturer covering up to the full commercial insurance copay or coinsurance amount [11]. The savings card has no income threshold for commercial plans.

Key eligibility rules:

• Must have commercial (private) insurance that covers Praluent
• Must not be enrolled in any federal or state government insurance program (Medicare, Medicaid, TRICARE, VA)
• The card applies only to FDA-approved indications
• Enrollment is done at Praluent.com or through the prescribing physician's office

Patients who lose commercial coverage midyear should contact the program immediately. The manufacturer also operates a Patient Assistance Program (PAP) for uninsured patients who meet income criteria, generally below 600% of the federal poverty level [11]. Kentucky patients applying for the PAP should work through their prescriber's office and expect a 4 to 6-week processing period.

Compounded Alirocumab in Kentucky: Legality and Cost

Compounded alirocumab from a 503A pharmacy is legal in Kentucky. A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients based on a valid prescription from a licensed prescriber [12]. Unlike 503B outsourcing facilities, which produce large batches for hospital systems, 503A pharmacies compound patient-specific preparations.

Several questions about compounded alirocumab deserve direct answers.

Is it the same molecule? Compounded alirocumab is formulated to match the active amino acid sequence of the branded product, but it is not manufactured under the same FDA-oversight conditions as Praluent. The FDA has not approved any compounded version of alirocumab [3]. Potency, sterility, and bioavailability data for compounded preparations have not been validated in large clinical trials.

What does it cost? Cost at Kentucky 503A pharmacies varies widely. Some pharmacies offer compounded alirocumab preparations at a fraction of the $580/month list price, with some patients paying well below $200 per month depending on the pharmacy and dose. A prescriber must determine whether the lower cost justifies the absence of FDA-reviewed manufacturing data.

Is alirocumab on the FDA shortage list? As of early 2025, alirocumab is not on the FDA drug shortage list [13]. Compounding of a drug that is not on shortage is permissible under 503A rules for patient-specific prescriptions but is not permitted for large-scale production or office stock under 503B rules. Prescribers in Kentucky should verify current shortage status before writing a compounding prescription, because 503B bulk compounding rules change when shortage status changes [12].

What should patients ask? Patients considering compounded alirocumab should ask the pharmacy for a Certificate of Analysis (CoA) from an independent, ISO-certified laboratory confirming potency and sterility for each lot. They should also confirm that the pharmacy holds a current Kentucky Board of Pharmacy license and that the prescribing clinician is licensed in Kentucky.

Telehealth Prescribing of Praluent in Kentucky

Kentucky permits telehealth prescribing of non-controlled prescription drugs, including Praluent. House Bill 167 (2022) and subsequent Kentucky Revised Statutes provisions allow a licensed Kentucky prescriber to establish a patient-prescriber relationship and order alirocumab via synchronous audiovisual telehealth, provided the prescriber conducts an appropriate medical evaluation and documents the clinical indication [14].

The telehealth prescriber must be licensed in Kentucky. Out-of-state clinicians relying solely on interstate telehealth compacts may prescribe to Kentucky residents only if they hold a Kentucky license or are covered under an applicable compact agreement that Kentucky has joined. As of 2025, Kentucky participates in the Interstate Medical Licensure Compact (IMLC), which covers physicians [14].

For a telehealth alirocumab consultation, patients should have recent lipid panel results (within 90 days), a medication list, and records of prior statin therapy available before the visit. The prescriber will order baseline LFTs and CK if not recently obtained, though the Praluent label does not require routine monitoring labs after initiation [3].

Telehealth platforms operating in Kentucky that specialize in cardiovascular and lipid management can complete PA paperwork, submit appeals, and enroll patients in the savings card program. Turnaround from initial visit to first injection can be as short as 7 to 14 days when insurance is already in place.

Comparing Praluent to Evolocumab (Repatha) on Cost and Coverage in Kentucky

Evolocumab (Repatha, Amgen) is the other FDA-approved monoclonal PCSK9 inhibitor available in Kentucky. Its list price is approximately $584 per month, nearly identical to alirocumab's [15]. The two drugs have similar LDL-lowering efficacy: alirocumab 150 mg every two weeks produced a 57.9% reduction in LDL-C in ODYSSEY MONO (N=103) [16], while evolocumab 140 mg every two weeks produced a 61.0% reduction in PROFICIO (pooled analysis, N>6,000) [15].

The FOURIER trial (N=27,564) showed evolocumab reduced the composite of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina by 15% relative risk reduction versus placebo (P<0.001) at a median follow-up of 2.2 years [17]. ODYSSEY OUTCOMES showed alirocumab reduced a similar composite by 15% at 2.8 years [4]. Neither drug has demonstrated superiority over the other in head-to-head cardiovascular outcomes data.

Kentucky insurance formularies sometimes prefer one over the other. A patient denied for Praluent may be approved for Repatha on the same plan, and vice versa. Prescribers should check formulary preference for each specific plan before writing the initial PA to avoid a delay. Some plans accept either agent for the first PA; others apply strict brand sequencing [9].

LDL-C Targets and When Alirocumab Is Indicated in Kentucky Patients

The 2022 ACC/AHA Guideline recommends an LDL-C goal of <70 mg/dL for very-high-risk ASCVD patients and <55 mg/dL for those with recurrent events [5]. For HeFH patients without ASCVD, the target is <100 mg/dL, or <70 mg/dL if another major risk factor is present [5].

Kentucky has a disproportionately high burden of cardiovascular disease. CDC data show Kentucky's age-adjusted cardiovascular disease mortality rate is 267.3 per 100,000, compared to the national average of 219.4 per 100,000 [18]. Obesity rates in Kentucky exceed 40%, and approximately 34% of Kentucky adults have hypertension, both conditions that compound ASCVD risk [18].

These population-level numbers mean Kentucky prescribers encounter a high volume of patients who legitimately need PCSK9 inhibitor therapy but face the cost barriers described above. A structured approach, beginning with statin optimization, adding ezetimibe (generic ezetimibe costs roughly $10 to $20 per month), then pursuing PA for alirocumab with guideline-concordant documentation, gives patients the best chance of achieving LDL-C targets within their insurance constraints.

Bempedoic acid (Nexletol) is an oral non-statin LDL-lowering agent that may help bridge patients who cannot access PCSK9 inhibitors. CLEAR Outcomes (N=13,970) showed bempedoic acid 180 mg daily reduced the composite of cardiovascular death, non-fatal MI, non-fatal stroke, or coronary revascularization by 13% relative risk reduction versus placebo (P<0.001) at a median follow-up of 40.6 months [19]. It does not require injection, which some Kentucky patients prefer.

Steps to Get Alirocumab at the Lowest Cost in Kentucky

Patients in Kentucky who need alirocumab should work through these specific steps with their prescriber.

First, confirm the clinical indication with a current lipid panel, not one older than 90 days. LDL-C above the guideline threshold on maximally tolerated statin therapy is the cornerstone of any PA request.

Second, add ezetimibe if not already prescribed. Ezetimibe 10 mg daily reduces LDL-C by an additional 15 to 25% [20]. Adding ezetimibe before requesting alirocumab satisfies step-therapy requirements and may itself achieve the LDL-C goal, avoiding the need for a PCSK9 inhibitor entirely.

Third, if LDL-C remains above target after ezetimibe, submit a PA for alirocumab with the complete documentation package: lipid panel, statin trial documentation, ezetimibe trial documentation, diagnosis code (HeFH or ASCVD), and, if available, genetic confirmation of FH.

Fourth, if PA is denied, appeal with a board-certified cardiologist or lipidologist co-signature and cite the ACC/AHA 2022 Class I Level A recommendation for PCSK9 inhibitors in very-high-risk ASCVD patients [5].

Fifth, if commercial insurance approves Praluent, enroll in the Regeneron/Sanofi savings card program immediately to reduce the copay to $0 per month [11].

Sixth, if Medicaid or Medicare is the coverage source and the savings card is ineligible, ask the prescriber whether a compounded alirocumab preparation from a Kentucky-licensed 503A pharmacy is appropriate given the clinical situation, and request a Certificate of Analysis for any compounded lot before administration.

Seventh, for Medicare Part D patients, check the Extra Help program (Low Income Subsidy). Patients with incomes below 150% of the federal poverty level may qualify for reduced Part D cost-sharing, which can meaningfully lower out-of-pocket costs for Tier 4 and Tier 5 drugs [6].

The starting dose of alirocumab for most patients is 75 mg subcutaneously every two weeks. If LDL-C response is inadequate after 8 to 12 weeks, the dose can be uptitrated to 150 mg every two weeks. A 300 mg every-four-weeks injection is FDA-approved as an alternative for patients who prefer monthly dosing [3].